Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of Physiologic Testing in PPI Non-Responders
NCT03202537Phase 1Completed
- Sponsor
- Northwestern University
- Start
- Jul 2017
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dexlansoprazole in gastroesophageal reflux disease (GERD), sponsored by Northwestern University. Primary endpoint: number of patients able to successfully withdraw from PPI treatment at 4.5 years. Started Jul 2017; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03202537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202537.